Here are highlights from the American Academy of Pain Medicine 23rd Annual Meeting

Sativex Oromucosal Spray

Contains delta-9-tetrahydrocannabinol and cannabidiol

  • Well tolerated in clinical studies
  • Cannabidiol reduces the psychoactive effects of tetrahydrocannabinol
  • Intoxication is less than with oral tetrahydrocannabinol

Sativex clinical studies in patients with multiple sclerosis

  • 160 outpatients with multiple sclerosis had a significant reduction of spasticity compared to placebo
  • Analysis of studies of 666 patients, showed that Sativex was significantly superior to placebo.

Sativex is approved in Canada to treat neuropathic pain generated in patients with multiple sclerosis. The US Food and Drug Administration has approved phase 3 studies to evaluate it in patients with cancer.

3/31/07 23:06 JR

Hi, I’m JR

John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.